|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, irrespective of receptor-mediated remnant clearance by the liver, liver-specific expression of human apoCI causes hypertriglyceridemia in the absence of the VLDLr and apoCIII.
|
16478678 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We assessed the effects on these complexes of placebo or 100-300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days.
|
26848137 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.
|
16861622 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
|
30073766 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.
|
2167514 |
1990 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at a level of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo high density lipoprotein (HDL) cholesterolemia 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p<0.001 for area under the receiver-operating characteristic curve).
|
27713142 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The less common allele (S2) of the SstI polymorphism on the 3' untranslated region of the APOC3 gene has been previously associated with increased triglycerides, total cholesterol (TC), and apoCIII levels and cardiovascular risk on several, but not all, studies.
|
11500189 |
2001 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism.
|
16495512 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Variation in the expression of apoC-III has been credibly documented to have an important role in hypertriglyceridemia.
|
11353333 |
2001 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.
|
30422238 |
2018 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Higher apoCIII concentrations were associated (P < .0001) with increased triglycerides (r = 0.78), total (r = 0.61) and low-density lipoprotein (LDL) (r = 0.40) cholesterol, apoA-I (r = 0.26), and apoB (r = 0.50), and these relationships persisted after controlling for age, gender, body mass index (BMI), and hemoglobin A1c (HbA1c).
|
15375785 |
2004 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In summary, hypertriglyceridemia in HuCIIITg mice appears to result primarily from decreased tissue uptake of triglyceride-rich particles from the circulation, which is most likely due to increased apo CIII and decreased apo E on VLDL particles. the HuCIIITg mouse appears to be a suitable animal model of primary familial hypertriglyceridemia, and these studies suggest a possible mechanism for this common lipoprotein disorder.
|
1430212 |
1992 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A cross experiment was done to determine the genetic background of hypertriglyceridemia observed in FLS mice. cDNA sequences of apoC-II and apoC-III of FLS mice were determined.
|
14506831 |
2003 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate whether hypertriglyceridemia subtypes affect acute pancreatitis progression, we analyzed two genetically modified hypertriglyceridemia mouse models-namely, glycosylphosphatidylinositol high-density lipoprotein binding protein 1 knockout (Gpihbp1-/-) and apolipoprotein C3 transgenic (ApoC3-tg) mice.
|
31570698 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that apoCIII and/or hypertriglyceridemia plays a major role in liver inflammation and cell death, which in turn increases susceptibility to and the severity of diet-induced NAFLD.
|
28163820 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
apoB = apolipoprotein B; apoC-III = apolipoprotein CIII; ASO = antisense oligonucleotide; FCS = familial chylomicronemia syndrome; HTG = hypertriglyceridemia; LPL = lipoprotein lipase; LPLD = lipoprotein lipase deficiency.
|
30183397 |
2018 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Higher apoCIII concentrations were associated (P<.0001) with increased triglycerides (r=.78), total (r=.61) and LDL (r=.40) cholesterol, apoAI (r=.26), and apoB (r=.50), AER (r=.08), and the severity of retinopathy (ETDRS score, r=.11), and these relationships persisted after controlling for age, gender, body mass index (BMI), and HbA1c level.
|
15642486 |
2005 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, RNAi-mediated ApoC3 inhibition lowered plasma TG concentrations in animals with diet-induced hypertriglyceridemia.
|
30723097 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The variant apo CIII promoter is common in the human population and may represent a major contributing factor to the development of hypertriglyceridemia.
|
8675624 |
1995 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Increases in postprandial apoCIII after fructose, but not glucose consumption, are positively associated with elevated triglycerides in large triglyceride-rich lipoproteins and increased small dense LDL levels.
|
31789670 |
2020 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that the metabolic response to HTG in human apolipoprotein C-III overexpressing mice may support a high TG production rate and that the cytosol of hepatocytes is subjected to an important oxidative stress, probably as a result of FFA over-accumulation, iron overload and enhanced activity of some ROS-producing catabolic enzymes.
|
25047818 |
2014 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease.
|
27770802 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.
|
26435212 |
2015 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well.
|
11483625 |
2001 |